BioCorRx
601 North Parkcenter Drive
Suite 103
Santa Ana
California
92705
United States
Tel: 512-267-2430
Website: http://bicxcorp.com/
Email: investors@BioCorRx.com
About BioCorRx
BioCorRx, Inc. (OTC: BICX) is a healthcare solutions company on the leading edge of addiction treatment. The company has developed a treatment program that is used by various independently owned treatment centers throughout the United States to treat alcoholism and opioid addiction.The program consists of two components:
BioCorRx, Inc. has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol or opioids for several months and as long as a year in some patients, depending on individual metabolism rates.
BioCorRx, Inc. also developed a counseling program that is tailored specifically to help those afflicted with addiction addicts prepare for life without abuse of their desired substance. Once a patient has received the implant, they are encouraged to enter the counseling program to maximize results.
BioCorRx, Inc.’s revolutionary addiction treatment program has a very high success rate as reported by patients in routine telephone and face to face interviews conducted by clinics using the program. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private counseling program without co-workers or family members knowing.
YEAR FOUNDED:
1999
LEADERSHIP:
CEO: Brady Granier
58 articles about BioCorRx
-
BioCorRx to Present at the LD Micro Invitational XII on June 7th
5/31/2022
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the LD Micro Invitational XII which is being held on June 7– 9, 2022.
-
BioCorRx Business Update for the First Quarter of 2022
5/17/2022
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments.
-
A roundup of last week's top clinical trial updates and news.
-
BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
4/27/2022
BioCorRx Inc. today announced that it has begun the recruiting and enrollment process for its first-in-human clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc.
-
BioCorRx Provides 2021 Year-End Business Update
4/1/2022
BioCorRx Inc. today provided a year-end business update for 2021 and reported on recent corporate developments.
-
A man paralyzed from amyotrophic lateral sclerosis (ALS) now has the ability to spell out his thoughts, thanks to an implanted electrode device that reads his brain signals.
-
BioCorRx to Participate in Two Upcoming Conferences - Mar 22, 2022
3/22/2022
BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that management will be participating in two upcoming conferences.
-
BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder
3/16/2022
BioCorRx Inc. (OTCQB: BICX) (the “Company”), today announced it has received Independent Institutional Review Board (IRB) approval for the Company’s Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled R&D subsidiary.
-
BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104
2/14/2022
BioCorRx Inc. is pleased to announce that it has completed its clinical trial agreement with Orange County Research Center for its first-in-human clinical trial of BICX104.
-
BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board
12/9/2021
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the appointment of Dr. Jie Shen to the Scientific Advisory Board (SAB).
-
BioCorRx to Participate in the Benzinga All Access Event on December 2nd
11/24/2021
BioCorRx Inc. today announced that Lourdes Felix, CEO, CFO and Director of BioCorRx, Inc. and Brady Granier, President and Director, CEO of BioCorRx Pharmaceuticals, will be participating in the Benzinga All Access event taking place on December 2, 2021.
-
BioCorRx Provides Business Update for the Third Quarter of 2021
11/16/2021
BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, provided a business update for the third quarter ended September 30, 2021 and reported on recent corporate developments.
-
BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant
10/7/2021
BioCorRx Inc. announced today that it has filed a patent application with the Russian Patent Office (Rospatent) for a biodegradable implant including naltrexone.
-
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
9/8/2021
Recro Pharma, Inc. and BioCorRx, Inc. announced the expansion of the companies’ ongoing relationship with the signing of a new development and manufacturing agreement.
-
BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
9/1/2021
BioCorRx Inc. announced today that it has been awarded approximately $3.5 million for the second phase of a grant which was awarded by the National Institute on Drug Abuse (NIDA)
-
BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board
6/22/2021
BioCorRx Inc today announced the addition of Dr. Ashok Kumar MSc DIoD FRCPath, Michael Howcroft, Priya Jambhekar, and Dr. Jeff Witkin to its Scientific Advisory Board (SAB).
-
BioCorRx Provides Business Update for the First Quarter of 2021
5/18/2021
BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the first quarter ended March 31, 2021 and reported on recent corporate developments.
-
BioCorRx Provides 2020 Year-End Business Update
4/1/2021
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2020 and reported on recent corporate developments.
-
BioCorRx Provides Business Update for the Second Quarter of 2020
8/14/2020
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2020. Brady Granier, CEO, and Director of BioCorRx, Inc., stated, “Despite the COVID-19 pandemic, our pivotal GLP preclinical studies of BICX102, a sustained release naltrexone implant for the treatment of opioid and a
-
BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic
5/22/2020
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update and reported on recent corporate developments. Brady Granier, CEO, and Director of BioCorRx, Inc., stated, “In light of uncertainties across many industries due to COVID-19, we wanted to reiterate that our pivotal GLP preclinical studies of BICX102, a sustai